CN1229116C - Injection of invermection for treating ox-warble myiosis - Google Patents
Injection of invermection for treating ox-warble myiosis Download PDFInfo
- Publication number
- CN1229116C CN1229116C CN 02160713 CN02160713A CN1229116C CN 1229116 C CN1229116 C CN 1229116C CN 02160713 CN02160713 CN 02160713 CN 02160713 A CN02160713 A CN 02160713A CN 1229116 C CN1229116 C CN 1229116C
- Authority
- CN
- China
- Prior art keywords
- ivermectin
- propylene glycol
- injection
- myiasis
- bovine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007924 injection Substances 0.000 title claims abstract description 22
- 238000002347 injection Methods 0.000 title claims abstract description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 54
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims abstract description 36
- 229960002418 ivermectin Drugs 0.000 claims abstract description 36
- 241000283690 Bos taurus Species 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims abstract description 10
- 238000001556 precipitation Methods 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 3
- 208000006123 Myiasis Diseases 0.000 claims abstract 6
- 201000004681 Psoriasis Diseases 0.000 claims abstract 3
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- GNMOPZKSTPABSN-UHFFFAOYSA-N dimethoxymethane;propane-1,2,3-triol Chemical compound COCOC.OCC(O)CO GNMOPZKSTPABSN-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- -1 Glycerin Methylal Propylene Glycol Chemical compound 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000010985 leather Substances 0.000 abstract description 4
- 239000003640 drug residue Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000013622 meat product Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 231100000111 LD50 Toxicity 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000202828 Dermatobia hominis Species 0.000 description 2
- PNVJTZOFSHSLTO-UHFFFAOYSA-N Fenthion Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000589 cicatrix Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000024241 parasitism Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003986 organophosphate insecticide Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种用于治疗牛皮蝇蛆病的伊维菌素注射液，以伊维菌素原粉为主要成份，其成份配比为：伊维菌素0.2-1.0、甘油甲缩醛20-100ml、丙二醇400-480ml；其制备方法为：按比例称取伊维菌素，甘油甲缩醛和丙二醇，于15℃-25℃室温状态下搅拌过夜，使伊维菌素充分溶解至溶液透明，容器底部无沉淀，溶液体表面无漂浮物后，加丙二醇并充分混匀，分装10lb/sq高压15分钟。本发明能够有效的预防和控制牛皮蝇蛆病，降低药物成本，降低肉品中的药物残留，疗效高、无毒副作用、增加了食品使用的安全度，提高了皮革价值。大规模的防治能大幅度的降低由牛皮蝇造成的经济损失，提高农牧民收入，具有非常重要的经济和社会效益。The invention discloses an ivermectin injection for treating bovine myiasis. The main component is ivermectin powder, and the composition ratio is: ivermectin 0.2-1.0, glycerin formal 20-100ml, propylene glycol 400-480ml; the preparation method is: weigh ivermectin, glycerin formal and propylene glycol in proportion, and stir overnight at room temperature of 15°C-25°C to fully dissolve ivermectin to After the solution is transparent, there is no precipitation at the bottom of the container, and there is no floating substance on the surface of the solution, add propylene glycol and mix well, then pack under high pressure of 10lb/sq for 15 minutes. The invention can effectively prevent and control bovine myiasis, reduce drug cost, reduce drug residue in meat products, have high curative effect, no toxic and side effects, increase the safety of food use, and increase the value of leather. Large-scale control can greatly reduce the economic loss caused by psoriasis, increase the income of farmers and herdsmen, and have very important economic and social benefits.
Description
(1) field under
The present invention relates to a kind of injection that is used for bomb fly in the animal and veterinary subject, is a kind of ivermectin injection that is used for the treatment of hypodermiasis in bovine specifically.
(2) background technology
The bovine livestock dermatobiasis is a kind of parasitic disease, and primary disease is in northern China large tracts of land branch, and is the most serious with northwest, northeast and pastoral area, the Inner Mongol especially, and at China's southern area, the cattle of being introduced by popular district only also has generation.Primary disease can cause the productivity of domestic animal to descend and sanitary condition descends, also cause hide discarded, bring great economic loss to animal husbandry: though adult does not bite cattle, but female fly circles in the air can cause when laying eggs that cattle is only uneasy, play kick, frightened and make normal life and search for food and be affected, with the passing of time cattle only becomes thin, sometimes " going mad " symptom only appears in cattle, causes once in a while to get injured by a fall or pregnant domestic animal miscarriage.When larva pierces skin, cause the skin sufferings, spirit is uneasy, and larva is divided a word with a hyphen at the end of a line in vivo, causes the tissue injury of portion of dividing a word with a hyphen at the end of a line.Particularly the 3rd the phase larva subcutaneous when parasitic at the back, cause local connective tissue proliferation and subcutaneous cellulitis, the formation fistula can suppurate during the secondary bacterial infection.Larva is left cicatrix behind the parasitism of back, influence leather and be worth.The toxin of torsalo larva, harmful to cattle blood only, can cause anemia.Suffer from poultry and become thin, meat reduces, and lactogenic female animal milk production descends.Indivedual suffering from, raise, and larva is strayed into medulla oblongata or brain parasitism, can cause nervous symptoms, even cause death.Once in a while as seen the allergy that causes because of the torsalo larva, results from the natural death of larva or mechanical deinsectization to squeeze broken larva body fluid and be absorbed and sensitization, when contacting antigen once more, anaphylaxis takes place promptly.Show as urticaria, or the swelling of eyelid, conjunctiva, labia, breast is arranged, shed tears sialorrhea, accelerated breathing.Since the reform and opening-up, in all parts of the country generally strengthened should disease preventing and controlling, but because most Therapeutic Method that adopts fenthion, though it is evident in efficacy, but fenthion is an organophosphorus insecticide, a large amount of uses continuously not only cause environmental pollution, cause meat, milk Chinese medicine residual quantity too high, the serious harm human health.In the recent period, EU Committee by bill, completely forbade Chinese livestock products from 2002 and enters European Union market at the bottom of calendar year 2001, and its main cause is a residue of veterinary drug.Yet for the prevention and the control of bomb fly disease, do not have still at present that a kind of residual quantity is little, price is low, curative effect is high, to healthy this type of the little medicine of harm humans.
(3) summary of the invention
The present invention is to reduce environmental pollution, to reduce the drug residue in the meat, solving problems such as prevention and control hypodermiasis in bovine is purpose, has developed that a kind of cost is low, curative effect is high, has had no side effect, can prevent and treat the special-purpose ivermectin microdosage of the bomb fly injection of bomb fly disease.
The technical scheme that realizes the object of the invention is:
A kind of ivermectin injection that is used for the treatment of hypodermiasis in bovine is characterized in that with the former powder of ivermectin be Main Ingredients and Appearance, and is formulated by following weight portion:
Ivermectin 0.2-1.0g
Glycerin methylal 20-100ml
Propylene glycol 400-480ml
Prepare by following process:
Accurately take by weighing ivermectin, measure required glycerin methylal and propylene glycol, stir down in 15 ℃ of-25 ℃ of room temperature states and spend the night, make ivermectin solution transparent, container bottom does not have precipitation, the no floating thing in solution body surface, be after ivermectin fully dissolves, to add propylene glycol, and abundant mixing.Packing 10lb/sq high pressure 15 minutes.
Beneficial effect is analyzed: the valid density that this medicine contains ivermectin is 0.04%, and using method is the cervical region subcutaneous injection: per 100 kg body weight are injected this medicine 1ml, can effectively prevent and control hypodermiasis in bovine.And the prescription valid density of the ivermectin of present most treatment bomb fly disease is 1%.The valid density of ivermectin reduces by 25 times than the valid density of the ivermectin in the commercially available treatment bomb fly disease medicament among the present invention, this has not only reduced the medicine production cost, but also greatly reduce drug residue, increased the degree of safety that food uses.Simultaneously, the best use of the present invention is the annual 9-11 month season; This moment, warble just just grew, and is higher to the sensitivity of medicine; Drug therapy is educated the death of bomb fly, it can not further be grown be the 3rd the phase larva, it is subcutaneous to travel to the back, Corii Bovis seu Bubali can not bore a hole, can not leave cicatrix yet, has improved leather value.The annual infected cattle torsalo animal in the whole nation reaches 4,000 ten thousand, and only the loss of leather aspect just reaches 200,000,000 yuans, and bomb fly mainly is popular in former revolutionary bases, minority-inhabited areas, frontier areas and poverty-stricken areas and the relatively backward area of economic civilization.Therefore, the special-purpose ivermectin microdosage of the bomb fly injection of the present invention's development may sell in above-mentioned area, has huge market potential; Large-scale control can significantly reduce the economic loss that is caused by bomb fly, improves peasants and herdsmen deeply, has very important economic and social benefit.
LD for this medicine
50Measure, undertaken, adopt intraperitoneal injection by the improvement karber's method of medicine acute toxicity test.The test branch is groped test, trial test and formal test three parts and is carried out.Laboratory animal is that 25-30 age in days Kunming is healthy mice (body weight 18-22g), and white mice is from Lanzhou Veterinary Inst., Chinese Academy of Agricultural Science laboratory animal field.
96 of the following white mice of formal test method and result, every group of 16 male and female half and half, totally 6 groups.One group of blank, 5 drug dose groups, the dose value of dosage group is geometric ratio and distributes, and logarithm value etc. are difference cloth, with the D of pilot study
MinBe minimum dose group, D
MinLogarithm value add group apart from i, be second group dosage logarithm value, use antilogarithm table, find the opposition numerical value of this value, this just obtains second group true dose value.Then, and the like.The fractional part round number of each dosage group during test.0.2ml/ medicine of every drug dose group injection, the medicine agent with more than the dosage that obtains, blank group injection 0.2ml/ two water that heat up in a steamer only.The body weight of white mice is by average 20g.The concentration and the dosage of grouping during formal test and medicine injection see Table 1.
The concentration and the dose form of table 1 formal test grouping and injection
Table 1 Grouping and injection dosage in the formal trial
| Group | Number of animals (only) Number of (rats) | Dosage logarithm value Dose Loggarithm | Dosage (mg/ kg) Dose (mg/g) | Injection concentration % Injection concentration% | Injection volume (ml) Injection dose (ml) |
| 1 | 16 | 1.5 | 32 | 0.32 | 0.2 |
| 2 | 16 | 1.66 | 46.8 | 0.47 | 0.2 |
| 3 | 16 | 1.82 | 66.1 | 0.66 | 0.2 |
| 4 | 16 | 1.98 | 95.5 | 0.96 | 0.2 |
| 5 | 16 | 2.14 | 138 | 1.38 | 0.2 |
| Contrast | 16 | 0.2 |
Medicine injection back is observed 3d and is write down active situation, poisoning symptom and the death condition of respectively organizing white mice.Formal test, what obtain the results are shown in Table 2.
Table 2 mice LD
50The measurement result table
Table 2.The results of LD
50 in rats
| Group | Dosage (mg/kg) Dose (mg/kg) | Log10 dose | Number of animals Number of animals | Death toll Number of mortality | P mortality rate Motality | Other relevant data |
| 1 | 32 | 1.5 | 16 | 4 | 0.25 | N=16 (every treated animal number) k=5 (packet count) i=0.16 Xm=2.14 ∑ p=2.625 ∑ p2=1.742 |
| 2 | 46.8 | 1.66 | 16 | 3 | 0.1875 | |
| 3 | 66.1 | 1.82 | 16 | 9 | 0.5625 | |
| 4 | 95.5 | 1.98 | 16 | 14 | 0.875 | |
| 5 | 138.0 | 2.14 | 16 | 12 | 0.75 | |
| Blank Control of group | Distilled water Double distilled water | 16 | 0 | 0 |
According to above result, calculate the LD of medicine with the formula that improves karber's method
50The median lethal dose(LD 50) formula of medicine is LD
50=log-1[X
k-i (∑
p-0.5)]
P is each group mortality rate in the formula, and i is the logarithm of ratio between adjacent two dosage, X
kBe the logarithm of maximal dose, ∑ is a summation.
LD
50＝log-1【2.14-0.16(2.625-0.5)】＝63.09mg/kg.bw
The control experiment: through using nearly 50000 yaks in the popular district of bomb fly in Gansu Province's God blessings county, Weiyuan County, Maqu County, Anxi county, cattle and pien niu, the ratio that the control animal does not have bomb fly is 95-100%.
(4) specific embodiment
Embodiment 1, in the conventional ratio preparation lot number of each component 010912 medicine: 50000ml
Ivermectin 20g
Glycerin methylal 2000ml
Propylene glycol 48000ml
Prepare by following process:
Accurately take by weighing ivermectin, measure required glycerin methylal and propylene glycol, stir down in 15 ℃ of room temperature states and spend the night, make ivermectin solution transparent, container bottom does not have precipitation, the no floating thing in solution body surface, be after ivermectin fully dissolves, to add propylene glycol, and abundant mixing.Packing 10lb/sq high pressure 15 minutes.
Embodiment 2, each component prepare in proportion lot number be 010913 medicine 20000ml wherein:
Ivermectin 8.0g
Glycerin methylal 2000ml
Propylene glycol 18000ml
Prepare by following process:
Accurately take by weighing ivermectin, measure required glycerin methylal and propylene glycol, stir down in 25 ℃ of room temperature states and spend the night, make ivermectin solution transparent, container bottom does not have precipitation, the no floating thing in solution body surface, be after ivermectin fully dissolves, add propylene glycol and abundant mixing.Packing 10lb/sq high pressure 15 minutes.
Embodiment 3, each component are 010914 medicine 40000ml in following ratio preparation lot number, wherein:
Ivermectin 16.0g
Glycerin methylal 8000ml
Propylene glycol 32000ml
Preparation method is with embodiment 1 or 2.
Embodiment: 4. press best proportion preparation 150000ml.Lot number: 020815.
Ivermectin 60g,
Glycerin methylal 6000ml,
Propylene glycol 144000ml
Preparation method is with embodiment 1 or 2.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02160713 CN1229116C (en) | 2002-12-31 | 2002-12-31 | Injection of invermection for treating ox-warble myiosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02160713 CN1229116C (en) | 2002-12-31 | 2002-12-31 | Injection of invermection for treating ox-warble myiosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513464A CN1513464A (en) | 2004-07-21 |
| CN1229116C true CN1229116C (en) | 2005-11-30 |
Family
ID=34237968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02160713 Expired - Fee Related CN1229116C (en) | 2002-12-31 | 2002-12-31 | Injection of invermection for treating ox-warble myiosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1229116C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655466A (en) * | 2013-11-18 | 2014-03-26 | 河南迪冉生物科技有限公司 | Ivermectin injection and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106811B (en) * | 2011-02-16 | 2012-07-04 | 成都师创生物医药科技有限公司 | Ivermectin mixed micelle injection and preparation method thereof |
-
2002
- 2002-12-31 CN CN 02160713 patent/CN1229116C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103655466A (en) * | 2013-11-18 | 2014-03-26 | 河南迪冉生物科技有限公司 | Ivermectin injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1513464A (en) | 2004-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60212964T2 (en) | COMPOSITIONS FOR THE TREATMENT OF ANIMAL DISEASES AND SYNDROMES WITH TRANSFER FACTOR | |
| RU2624868C2 (en) | Preparation method of the complex gel for mastitis treatment and prevention in cows and complex gel on its basis | |
| CN104435023B (en) | A kind of Chinese medical extract and its application | |
| CN1229116C (en) | Injection of invermection for treating ox-warble myiosis | |
| RU2537143C1 (en) | Preparation for treatment and prevention of mastitis in cows | |
| RU2327453C2 (en) | Composition applied for animals' infectious diseases prevention | |
| Hamel et al. | Gamithromycin in sheep: Pharmacokinetics and clinical evaluation against ovine footrot | |
| RU2351151C1 (en) | Method of increasing resistance of organism of broilers | |
| CN111514157A (en) | Application of composition in preparation of veterinary anti-parasitic drug, veterinary anti-parasitic transdermal solution and preparation method thereof | |
| Buckingham | Case report. Pheochromocytoma in a mare | |
| RU2294209C1 (en) | Immunomodulating preparation | |
| RU2715432C1 (en) | Antiparasitic agent for treatment and prevention of animals by voluntary feeding | |
| CN114425036A (en) | Basic tylosin injection and preparation method thereof | |
| RU2549496C1 (en) | Homeopathic medicinal product having stress-protective and growth-stimulating effect, regulating metabolism in young farm animals and poultry | |
| RU2381802C1 (en) | Preparation for treatment and prevention of infectious keratoconjunctivitis in cattle and method for application thereof | |
| RU2817414C1 (en) | Method for improving immune status of young pigs using phytocomposition | |
| RU2804131C1 (en) | Method for increasing the productivity of calves using a phytogenic feed additive | |
| RU2796674C1 (en) | Method of increasing the overall immunobiological reactivity of the body of calves | |
| CN103417477A (en) | Doramectin O/W type injection taking water as matrix and preparation method thereof | |
| RU2813546C1 (en) | Product for treatment and prevention of postpartum diseases in cows | |
| CN115350170B (en) | Application of taurine in preparation of medicine for improving antiviral parotitis capability of Chinese softshell turtles | |
| CN116196322B (en) | Pharmaceutical composition containing juglone and ivermectin for preventing and treating animal acariasis and application thereof | |
| CN113244220A (en) | Application of potassium dehydroandrographolide succinate in preparation of veterinary drug for treating cow mastitis and potassium dehydroandrographolide succinate veterinary drug | |
| CN101822706A (en) | Gynostemma pellet preparation for preventing subclinical mastitis and preparation method thereof | |
| RU2297839C1 (en) | Medicinal agent for treatment of actinomycosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051130 Termination date: 20100201 |